O-5 INTEGRATED ANALYSIS OF ARCHAEAL, FUNGAL AND PROTOZOAN GUT TRANSCRIPTOME IN METABOLIC ASSOCIATED FATTY LIVER DISEASE (MAFLD) IN ARGENTINA

Fungi, archaea and protozoa are the least known members of the gut microbiome, but they could represent a niche for biomarkers discovery to risk-stratify MAFLD patients. This study aimed to identify gut metatranscriptomic signatures in MAFLD patients from Argentina. Stool samples, diet, demographic...

Full description

Saved in:
Bibliographic Details
Published inAnnals of hepatology Vol. 28; p. 101015
Main Authors Suárez, Bárbara, Mascardi, María Florencia, Mazzini, Flavia Noelia, Vera, M. Ruda, Marciano, Sebastián, Casciato, Paola, Narvaez, Adrián, Haddad, Leila, Anders, Margarita, Orozco, Federico, Tamaroff, Ana Jesica, Cook, Frank, Gounarides, John, Gutt, Susana, Gadano, Adrián, dez García, Celia Mén, Marro, Martin L., Steinhardt, Alberto Penas, Trinks, Julieta
Format Journal Article
LanguageEnglish
Published Elsevier España, S.L.U 01.03.2023
Elsevier
Subjects
Online AccessGet full text
ISSN1665-2681
2659-5982
DOI10.1016/j.aohep.2023.101015

Cover

Abstract Fungi, archaea and protozoa are the least known members of the gut microbiome, but they could represent a niche for biomarkers discovery to risk-stratify MAFLD patients. This study aimed to identify gut metatranscriptomic signatures in MAFLD patients from Argentina. Stool samples, diet, demographic and clinical data were obtained from 33 biopsy-proven MAFLD patients (12 simple steatosis (SS) / 21 steatohepatitis (SH)) and 19 healthy volunteers (HV). PNPLA3 rs738409 SNP was genotyped. RNA-seq was performed in NovaSeq6000®. Data were analyzed with Maaslin2-v1.2.0, bioBakery-v1.8 and DESeq2-v4.1. BMI was higher among MAFLD patients than in HV (q=4.49 × 10−6). The risk GG genotype of PNPLA3-SNP was more prevalent among SH (q=0.0198). In MAFLD patients and in subjects with the GG genotype, differentially expressed genes (DEGs) of fungi, such as Fusarium proliferatum and Candida sorbophila, were up-regulated (q<0.01). After comparing transcript abundance, Saccharomucetaceae was the most active family among MAFLD patients, whereas Aspergillaceae family prevailed in HV. DEGs of methanogenic archaea and protozoa, such as Fonticula alba and Blastocystis spp., were highly expressed in MAFLD and SH after comparing them to HV and SS groups, respectively. The analysis of the functionally active protozoan families revealed that the Blastocystidae and Fonticulidae families were more functionally abundant in MAFLD and SH groups after comparing to HV and SS, respectively (Figure exhibits the statistically significant differences between groups). In subjects with the GG genotype, DEGs of Fonticula alba were up-regulated and those of Blastocystis spp. were less expressed after comparing to those with CC/CG genotypes. In SH, functional profiling of archaeal and fungal DEGs revealed an over-representation of viral capsid assembly and phage shock processes, whereas copper metabolism, peptidoglycan turnover and non-autophagic vacuolization were enriched by protozoan DEGs. The switch in microbiome signatures characteristic of MAFLD onset and progression is achieved through the activity of several community members.
AbstractList Fungi, archaea and protozoa are the least known members of the gut microbiome, but they could represent a niche for biomarkers discovery to risk-stratify MAFLD patients. This study aimed to identify gut metatranscriptomic signatures in MAFLD patients from Argentina. Stool samples, diet, demographic and clinical data were obtained from 33 biopsy-proven MAFLD patients (12 simple steatosis (SS) / 21 steatohepatitis (SH)) and 19 healthy volunteers (HV). PNPLA3 rs738409 SNP was genotyped. RNA-seq was performed in NovaSeq6000®. Data were analyzed with Maaslin2-v1.2.0, bioBakery-v1.8 and DESeq2-v4.1. BMI was higher among MAFLD patients than in HV (q=4.49 × 10−6). The risk GG genotype of PNPLA3-SNP was more prevalent among SH (q=0.0198). In MAFLD patients and in subjects with the GG genotype, differentially expressed genes (DEGs) of fungi, such as Fusarium proliferatum and Candida sorbophila, were up-regulated (q<0.01). After comparing transcript abundance, Saccharomucetaceae was the most active family among MAFLD patients, whereas Aspergillaceae family prevailed in HV. DEGs of methanogenic archaea and protozoa, such as Fonticula alba and Blastocystis spp., were highly expressed in MAFLD and SH after comparing them to HV and SS groups, respectively. The analysis of the functionally active protozoan families revealed that the Blastocystidae and Fonticulidae families were more functionally abundant in MAFLD and SH groups after comparing to HV and SS, respectively (Figure exhibits the statistically significant differences between groups). In subjects with the GG genotype, DEGs of Fonticula alba were up-regulated and those of Blastocystis spp. were less expressed after comparing to those with CC/CG genotypes. In SH, functional profiling of archaeal and fungal DEGs revealed an over-representation of viral capsid assembly and phage shock processes, whereas copper metabolism, peptidoglycan turnover and non-autophagic vacuolization were enriched by protozoan DEGs. The switch in microbiome signatures characteristic of MAFLD onset and progression is achieved through the activity of several community members.
Introduction and ObjectivesFungi, archaea and protozoa are the least known members of the gut microbiome, but they could represent a niche for biomarkers discovery to risk-stratify MAFLD patients. This study aimed to identify gut metatranscriptomic signatures in MAFLD patients from Argentina. Materials and MethodsStool samples, diet, demographic and clinical data were obtained from 33 biopsy-proven MAFLD patients (12 simple steatosis (SS) / 21 steatohepatitis (SH)) and 19 healthy volunteers (HV). PNPLA3 rs738409 SNP was genotyped. RNA-seq was performed in NovaSeq6000®. Data were analyzed with Maaslin2-v1.2.0, bioBakery-v1.8 and DESeq2-v4.1. ResultsBMI was higher among MAFLD patients than in HV (q=4.49 × 10 −6). The risk GG genotype of PNPLA3-SNP was more prevalent among SH (q=0.0198). In MAFLD patients and in subjects with the GG genotype, differentially expressed genes (DEGs) of fungi, such as Fusarium proliferatum and Candida sorbophila, were up-regulated (q<0.01). After comparing transcript abundance, Saccharomucetaceae was the most active family among MAFLD patients, whereas Aspergillaceae family prevailed in HV. DEGs of methanogenic archaea and protozoa, such as Fonticula alba and Blastocystis spp., were highly expressed in MAFLD and SH after comparing them to HV and SS groups, respectively. The analysis of the functionally active protozoan families revealed that the Blastocystidae and Fonticulidae families were more functionally abundant in MAFLD and SH groups after comparing to HV and SS, respectively (Figure exhibits the statistically significant differences between groups). In subjects with the GG genotype, DEGs of Fonticula alba were up-regulated and those of Blastocystis spp. were less expressed after comparing to those with CC/CG genotypes. In SH, functional profiling of archaeal and fungal DEGs revealed an over-representation of viral capsid assembly and phage shock processes, whereas copper metabolism, peptidoglycan turnover and non-autophagic vacuolization were enriched by protozoan DEGs. ConclusionsThe switch in microbiome signatures characteristic of MAFLD onset and progression is achieved through the activity of several community members.
Introduction and Objectives: Fungi, archaea and protozoa are the least known members of the gut microbiome, but they could represent a niche for biomarkers discovery to risk-stratify MAFLD patients. This study aimed to identify gut metatranscriptomic signatures in MAFLD patients from Argentina. Materials and Methods: Stool samples, diet, demographic and clinical data were obtained from 33 biopsy-proven MAFLD patients (12 simple steatosis (SS) / 21 steatohepatitis (SH)) and 19 healthy volunteers (HV). PNPLA3 rs738409 SNP was genotyped. RNA-seq was performed in NovaSeq6000®. Data were analyzed with Maaslin2-v1.2.0, bioBakery-v1.8 and DESeq2-v4.1. Results: BMI was higher among MAFLD patients than in HV (q=4.49 × 10−6). The risk GG genotype of PNPLA3-SNP was more prevalent among SH (q=0.0198). In MAFLD patients and in subjects with the GG genotype, differentially expressed genes (DEGs) of fungi, such as Fusarium proliferatum and Candida sorbophila, were up-regulated (q<0.01). After comparing transcript abundance, Saccharomucetaceae was the most active family among MAFLD patients, whereas Aspergillaceae family prevailed in HV. DEGs of methanogenic archaea and protozoa, such as Fonticula alba and Blastocystis spp., were highly expressed in MAFLD and SH after comparing them to HV and SS groups, respectively. The analysis of the functionally active protozoan families revealed that the Blastocystidae and Fonticulidae families were more functionally abundant in MAFLD and SH groups after comparing to HV and SS, respectively (Figure exhibits the statistically significant differences between groups). In subjects with the GG genotype, DEGs of Fonticula alba were up-regulated and those of Blastocystis spp. were less expressed after comparing to those with CC/CG genotypes. In SH, functional profiling of archaeal and fungal DEGs revealed an over-representation of viral capsid assembly and phage shock processes, whereas copper metabolism, peptidoglycan turnover and non-autophagic vacuolization were enriched by protozoan DEGs. Conclusions: The switch in microbiome signatures characteristic of MAFLD onset and progression is achieved through the activity of several community members.
ArticleNumber 101015
Author Trinks, Julieta
Narvaez, Adrián
Marro, Martin L.
Mazzini, Flavia Noelia
dez García, Celia Mén
Haddad, Leila
Suárez, Bárbara
Cook, Frank
Tamaroff, Ana Jesica
Gutt, Susana
Casciato, Paola
Marciano, Sebastián
Gounarides, John
Mascardi, María Florencia
Vera, M. Ruda
Steinhardt, Alberto Penas
Anders, Margarita
Orozco, Federico
Gadano, Adrián
Author_xml – sequence: 1
  givenname: Bárbara
  surname: Suárez
  fullname: Suárez, Bárbara
  organization: 1 Institute of Translational Medicine and Biomedical Engineering (IMTIB) - Conicet University Institute of the Italian Hospital. Buenos Aires Italian Hospital. Buenos Aires, Argentina
– sequence: 2
  givenname: María Florencia
  surname: Mascardi
  fullname: Mascardi, María Florencia
  organization: 1 Institute of Translational Medicine and Biomedical Engineering (IMTIB) - Conicet University Institute of the Italian Hospital. Buenos Aires Italian Hospital. Buenos Aires, Argentina
– sequence: 3
  givenname: Flavia Noelia
  surname: Mazzini
  fullname: Mazzini, Flavia Noelia
  organization: 1 Institute of Translational Medicine and Biomedical Engineering (IMTIB) - Conicet University Institute of the Italian Hospital. Buenos Aires Italian Hospital. Buenos Aires, Argentina
– sequence: 4
  givenname: M. Ruda
  surname: Vera
  fullname: Vera, M. Ruda
  organization: Biotherapeutic and Analytical Technologies, Novartis Institutes for Biomedical Research, Cambridge (NIBR), MA, United States of America
– sequence: 5
  givenname: Sebastián
  surname: Marciano
  fullname: Marciano, Sebastián
  organization: Liver Unit of Buenos Aires Italian Hospital. Buenos Aires, Argentina
– sequence: 6
  givenname: Paola
  surname: Casciato
  fullname: Casciato, Paola
  organization: National Council for Scientific and Technical Research (CONICET), Buenos Aires, Argentina
– sequence: 7
  givenname: Adrián
  surname: Narvaez
  fullname: Narvaez, Adrián
  organization: Liver Unit of Buenos Aires Italian Hospital. Buenos Aires, Argentina
– sequence: 8
  givenname: Leila
  surname: Haddad
  fullname: Haddad, Leila
  organization: Liver Unit of Buenos Aires Italian Hospital. Buenos Aires, Argentina
– sequence: 9
  givenname: Margarita
  surname: Anders
  fullname: Anders, Margarita
  organization: Liver Unit of German Hospital, Buenos Aires, Argentina
– sequence: 10
  givenname: Federico
  surname: Orozco
  fullname: Orozco, Federico
  organization: Liver Unit of German Hospital, Buenos Aires, Argentina
– sequence: 11
  givenname: Ana Jesica
  surname: Tamaroff
  fullname: Tamaroff, Ana Jesica
  organization: Nutrition Department of Buenos Aires Italian Hospital. Buenos Aires, Argentina
– sequence: 12
  givenname: Frank
  surname: Cook
  fullname: Cook, Frank
  organization: Analytical Sciences & Imaging Department, NIBR, Cambridge, MA, United States of America
– sequence: 13
  givenname: John
  surname: Gounarides
  fullname: Gounarides, John
  organization: Analytical Sciences & Imaging Department, NIBR, Cambridge, MA, United States of America
– sequence: 14
  givenname: Susana
  surname: Gutt
  fullname: Gutt, Susana
  organization: Nutrition Department of Buenos Aires Italian Hospital. Buenos Aires, Argentina
– sequence: 15
  givenname: Adrián
  surname: Gadano
  fullname: Gadano, Adrián
  organization: Liver Unit of Buenos Aires Italian Hospital. Buenos Aires, Argentina
– sequence: 16
  givenname: Celia Mén
  surname: dez García
  fullname: dez García, Celia Mén
  organization: Chemical Biology & Therapeutics, NIBR, Cambridge, MA, United States of America
– sequence: 17
  givenname: Martin L.
  surname: Marro
  fullname: Marro, Martin L.
  organization: Cardiovascular and Metabolic Disease Area, NIBR, Cambridge, MA, United States of America
– sequence: 18
  givenname: Alberto Penas
  surname: Steinhardt
  fullname: Steinhardt, Alberto Penas
  organization: National Council for Scientific and Technical Research (CONICET), Buenos Aires, Argentina
– sequence: 19
  givenname: Julieta
  surname: Trinks
  fullname: Trinks, Julieta
  organization: 1 Institute of Translational Medicine and Biomedical Engineering (IMTIB) - Conicet University Institute of the Italian Hospital. Buenos Aires Italian Hospital. Buenos Aires, Argentina
BookMark eNqFkd-K1DAUh4Os4OzqE3iTSwU75k_TNohC7KTdQqdd2oyw3oQ0k2rHsV3aVdh38KFtZ8QLQfYqhxN-X3LOdwku-qF3ALzEaI0RDt4e1mb46u7WBBG6dBBmT8CKBIx7jEfkAqxwEDCPBBF-Bi6n6YCQTxkmK_Cr9BjMCiXTSii5gaIQ-W2d1bBMoKjiayFF_gYmuyIV-Xy5gTdVqcrPpShgulNQVaKo4yq7UeVWzhy4lUp8LPMshqKuyzg7QROh1C3Ms0-ygpuslqKW8NVWJPnm9ZIRVSoLlRXiOXjamuPkXvw5r8AukSq-9vIyzWKRe5bieYzIWUdYw0PqAhbxCEWWOtwS1FracL-ZS9K2lCNKcOTzxhjWYMctYczsmR_SK5CdufvBHPTd2H0344MeTKdPjWH8os1439mj0yy0AbE8xIiGPseI7wOKSeQz7NMQm2Bm0TPLjsM0ja79y8NIL3L0QZ_k6EWOPsuZU-_PKTeP-bNzo55s53rr9t3o7P38j-6R_Id_8vbY9Z01x2_uwU2H4cfYzxvUWE9EI10v-hf7hCKEMecz4N3_AY8-_xv3oLTa
ContentType Journal Article
Copyright 2023
Copyright_xml – notice: 2023
DBID 6I.
AAFTH
AAYXX
CITATION
DOA
DOI 10.1016/j.aohep.2023.101015
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
DatabaseTitleList



Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ (Directory of Open Access Journals)
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2659-5982
EndPage 101015
ExternalDocumentID oai_doaj_org_article_57c62c97103749109d631284514371a6
10_1016_j_aohep_2023_101015
S1665268123001199
1_s2_0_S1665268123001199
GroupedDBID ---
.1-
.FO
0R~
1P~
23M
2WC
53G
5GY
77H
AAEDW
AAKDD
AALRI
AAXUO
AAYWO
ABXHO
ACVFH
ADBBV
ADCNI
ADVLN
AENEX
AEUPX
AEVXI
AEXQZ
AFJKZ
AFPUW
AFRHN
AIGII
AITUG
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
APOWU
APXCP
BAWUL
EBD
EBS
EMOBN
F5P
FDB
GROUPED_DOAJ
GX1
M41
OC.
OK1
ON0
P2P
ROL
RSH
SV3
TR2
Z5R
AFCTW
DIK
NCXOZ
0SF
6I.
AAFTH
AAYXX
CITATION
ID FETCH-LOGICAL-c3165-8ece25b973e6589808c3e1f20fc3b94b1f22ff390321849baa5b1e9c255ad5473
IEDL.DBID DOA
ISSN 1665-2681
IngestDate Wed Aug 27 01:17:04 EDT 2025
Wed Oct 01 01:35:08 EDT 2025
Thu Jul 20 20:09:28 EDT 2023
Sun Feb 23 10:19:43 EST 2025
Tue Aug 26 16:40:54 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License http://creativecommons.org/licenses/by-nc-nd/4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3165-8ece25b973e6589808c3e1f20fc3b94b1f22ff390321849baa5b1e9c255ad5473
OpenAccessLink https://doaj.org/article/57c62c97103749109d631284514371a6
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_57c62c97103749109d631284514371a6
crossref_primary_10_1016_j_aohep_2023_101015
elsevier_sciencedirect_doi_10_1016_j_aohep_2023_101015
elsevier_clinicalkeyesjournals_1_s2_0_S1665268123001199
elsevier_clinicalkey_doi_10_1016_j_aohep_2023_101015
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate March 2023
PublicationDateYYYYMMDD 2023-03-01
PublicationDate_xml – month: 03
  year: 2023
  text: March 2023
PublicationDecade 2020
PublicationTitle Annals of hepatology
PublicationYear 2023
Publisher Elsevier España, S.L.U
Elsevier
Publisher_xml – name: Elsevier España, S.L.U
– name: Elsevier
SSID ssj0043512
Score 2.3099437
Snippet Fungi, archaea and protozoa are the least known members of the gut microbiome, but they could represent a niche for biomarkers discovery to risk-stratify MAFLD...
Introduction and ObjectivesFungi, archaea and protozoa are the least known members of the gut microbiome, but they could represent a niche for biomarkers...
Introduction and Objectives: Fungi, archaea and protozoa are the least known members of the gut microbiome, but they could represent a niche for biomarkers...
SourceID doaj
crossref
elsevier
SourceType Open Website
Index Database
Publisher
StartPage 101015
SubjectTerms Gastroenterology and Hepatology
Title O-5 INTEGRATED ANALYSIS OF ARCHAEAL, FUNGAL AND PROTOZOAN GUT TRANSCRIPTOME IN METABOLIC ASSOCIATED FATTY LIVER DISEASE (MAFLD) IN ARGENTINA
URI https://www.clinicalkey.com/#!/content/1-s2.0-S1665268123001199
https://www.clinicalkey.es/playcontent/1-s2.0-S1665268123001199
https://dx.doi.org/10.1016/j.aohep.2023.101015
https://doaj.org/article/57c62c97103749109d631284514371a6
Volume 28
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ (Directory of Open Access Journals)
  customDbUrl:
  eissn: 2659-5982
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0043512
  issn: 1665-2681
  databaseCode: DOA
  dateStart: 20190101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 2659-5982
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0043512
  issn: 1665-2681
  databaseCode: GX1
  dateStart: 0
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVLSH
  databaseName: Elsevier Journals
  customDbUrl:
  mediaType: online
  eissn: 2659-5982
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0043512
  issn: 1665-2681
  databaseCode: AKRWK
  dateStart: 20020101
  isFulltext: true
  providerName: Library Specific Holdings
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb5wwELaqHKpeqj7V7SPyIYdWChLYvHx0dmFDxUIE3irpxQJjlPawqbrpv-iPjseGaA9VcukNGTzAzHge8vgbhE6GYEyHOGaeGunohSoMPZZEvdcx4w1S0qdssNUWVXy-Db9eRpcHrb6gJszBAzvGmYRdxUSxBM6zhca3sSGmYFPB0SdBZ8G2jRubkylng00M4PY5Y1vDlQYz3pCt7OpurjVAVRIKIz50xD3wSRa6_8A1Hbib_AV6PsWJmLvve4me6N0r9HQz7YS_Rn9rL8KAZ7tuuDE-mFe8vGqLFtc5hg0gnvHyFOfbas1Lc3OFL5pa1N9rXuH1VmDR8KpdNsWFqDeZoYM3meBndVkssQV6LCzRnAtxhcviW9bgVdFmvM3w5w3Py9UXmMObdVaJouJv0DbPxPLcmzoreIoGhiWpVppEPUuoNhEIS_1UUR2MxB8V7VnYm0syjpT5FDJA1ndd1AeaKZN_dAN0K36LjnY3O_0O4SgNFCWd6jTg9AxRFyljN1RKhiQe_J4s0OnMW_nLAWjIubLsp7SikCAK6USxQGfA__tHAf3aDhidkJNOyMd0YoHCWXpyPmBqTKIh9OPhdyf_mqb307Ley0DuifRlC3oFamXyN8DMYwsU38-cIhcXkTz2yvf_43c_oGdA0hURf0RHt7__6E8mVLrtj-2quAM6V_zZ
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=O-5+INTEGRATED+ANALYSIS+OF+ARCHAEAL%2C+FUNGAL+AND+PROTOZOAN+GUT+TRANSCRIPTOME+IN+METABOLIC+ASSOCIATED+FATTY+LIVER+DISEASE+%28MAFLD%29+IN+ARGENTINA&rft.jtitle=Annals+of+hepatology&rft.au=Su%C3%A1rez%2C+B%C3%A1rbara&rft.au=Mascardi%2C+Mar%C3%ADa+Florencia&rft.au=Mazzini%2C+Flavia+Noelia&rft.au=Vera%2C+M.+Ruda&rft.date=2023-03-01&rft.pub=Elsevier+Espa%C3%B1a%2C+S.L.U&rft.issn=1665-2681&rft.volume=28&rft_id=info:doi/10.1016%2Fj.aohep.2023.101015&rft.externalDocID=S1665268123001199
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F16652681%2FS1665268123X00039%2Fcov150h.gif